Biomedical Systems Announces Expanded Participation In The Avoca Diligent Prequalification Platform

Diligent Leverages Avoca Quality Consortium Standards Improve Quality and Reduce Cycle Time in the Prequalification of Technical Providers

ST. LOUIS--(BUSINESS WIRE)--Biomedical Systems is pleased to announce its participation in the Avoca Diligent Prequalification Platform. The purpose of this initiative is to increase quality, improve efficiency, reduce risk, and accelerate technical service provider onboarding by centralizing aspects of prequalification activities.

“This is another example of how Biomedical Systems is using innovative approaches to truly create a better clinical trial experience. Through this collaboration, Biomedical Systems and Avoca will continue to drive innovation, standardization and streamlining to drug development processes.”

Diligent started by engaging an expert Advisory Board from the Avoca Quality Consortium to develop Industry Standards for Prequalification of technical service providers. These standards were mapped, when possible, to health authority regulations or regulatory guidance. They underwent a rigorous review by The Avoca Group, The Advisory Board, and companies in the industry that deliver these technical services. Upon finalizing the Prequalification Industry Standards, prequalification tools were developed that map back to these standards, including Request for Information (RFI) templates.

The Avoca Group has been inviting leading technical service providers to complete core and technical RFI templates and centralize them so they are readily available to sponsors (and CROs, if applicable), to speed up the process of prequalifying and onboarding new technical providers. Biomedical Systems is an early adopter for this transformational initiative and invites sponsors and CROs to contact The Avoca Group at Diligent@theavocagroup.com to request these completed RFIs as needed to accelerate their review and onboarding of Biomedical Systems for their clinical trials.

“The Avoca Group is pleased that Biomedical Systems has decided to expand its participation in Diligent to include eCOA services,” said Patricia Leuchten, CEO of The Avoca Group. “This is another example of how Biomedical Systems is using innovative approaches to truly create a better clinical trial experience. Through this collaboration, Biomedical Systems and Avoca will continue to drive innovation, standardization and streamlining to drug development processes.”

“We are thrilled to be adding yet another service to our participation in this program. We strive to embark upon initiatives, such as this, to increase efficiencies for our sponsor and CRO partners,” said Bob Mills, Executive VP of Sales and Marketing, Biomedical Systems.

About Biomedical Systems

Biomedical Systems is a premier global provider of centralized diagnostic services.

Founded in 1975, Biomedical Systems has grown to be a leading clinical trial provider to pharmaceutical, medical device, biotech, and CROs. Its comprehensive clinical trial solutions include cardiac safety, pulmonary function, imaging, eCOA, and scientific affairs.

Biomedical Systems’ corporate headquarters is located in St. Louis, Missouri. European headquarters is located in Brussels, Belgium with supporting offices in Japan, China and India, which are able to resupply equipment and materials to challenging areas around the world in a timely, cost-effective manner. Its global staff speaks 21 languages, facilitating communication with international sponsors and sites delivering better quality data. With five strategically located offices spanning the globe, Biomedical Systems has managed thousands of clinical trials in over 95 countries and can offer services and support 24 hours a day. For more information, visit http://www.biomedsys.com/.